CD133+ HCC cells display enhanced CSC features, including the ability to grow in cell suspension aggregates (spheroids), the upregulation of stemness-associated (Oct4, KLF4, CD4, EpCAM) and drug-resistant (ABCG2) genes, and the increased resistance to sorafenib. The gene discussed is ABCG2; the disease is hepatocellular carcinoma.